Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer

Friday, August 31, 2007 General News J E 4
WASHINGTON, Aug. 30 Prestwick Pharmaceuticals, Inc., aprivately-held biotechnology company, today announced that it has hiredMartin Stogniew, Ph.D. as Executive Vice President, Chief TechnologyOfficer.

Dr. Stogniew will be responsible for Prestwick's pre-clinicaldevelopment, regulatory and patent activities around its portfolio ofproducts including its lead product candidate, tetrabenazine, a highlyselective and reversible dopamine depletor in Phase 3 clinical trialsfor potential use as a treatment for chorea associated with Huntington'sDisease.

He joins Prestwick most recently from Zelos Therapeutics, where he wasExecutive Vice President of Development responsible for pre-clinical,regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name,Marty will immediately help Prestwick as we work to execute and enhanceour pipeline," said George F. Horner III, President and Chief ExecutiveOfficer of Prestwick. "He has made a significant impact in thedevelopment of successful drugs such as Anidulafugin, Amifostine andIdarubicin -- all of which are now on the market and positively impactingpatients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. asExecutive Vice President of Scientific Affairs from 2001 to 2005 beforeVicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior toVicuron, Dr. Stogniew served as Chief Scientific Officer at NextPharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciencesat MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and aB.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline productcandidates being studied for CNS conditions with significant unmetneeds, including Huntington's disease, Parkinson's disease, restlesslegs syndrome, schizophrenia, autism, Alzheimer's disease and sleepapnea.

Please go to for more information.

SOURCE Prestwick Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
A Worldwide Phase III Clinical Trial Seeks U.S. Pa...
VaxGen Files 2006 Financial Statements and Provide...